Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia

BACKGROUND: An individualised risk-stratified screening for prostate cancer (PCa) would select the patients who will benefit from further investigations as well as therapy. Current detection methods suffer from low sensitivity and specificity, especially for separating PCa from benign prostatic cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Giskeødegård, Guro F, Hansen, Ailin Falkmo, Bertilsson, Helena, Gonzalez, Susana Villa, Kristiansen, Kåre Andre, Bruheim, Per, Mjøs, Svein A, Angelsen, Anders, Bathen, Tone Frost, Tessem, May-Britt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702000/
https://www.ncbi.nlm.nih.gov/pubmed/26633561
http://dx.doi.org/10.1038/bjc.2015.411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702000/
https://www.ncbi.nlm.nih.gov/pubmed/26633561
http://dx.doi.org/10.1038/bjc.2015.411

Ejemplares similares